Segaert S - Search Results

1

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.

Segaert S, Van Cutsem E. Segaert S, et al. Ann Oncol. 2005 Sep;16(9):1425-33. doi: 10.1093/annonc/mdi279. Epub 2005 Jul 12. Ann Oncol. 2005. PMID: 16012181 Free article.

2

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.

Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan T, Morere JF, Santoro A, Sobrero A, Van Cutsem E, Layton A. Segaert S, et al. J Dtsch Dermatol Ges. 2005 Aug;3(8):599-606. doi: 10.1111/j.1610-0387.2005.05058.x. J Dtsch Dermatol Ges. 2005. PMID: 16033478 Review.

3

Clinical management of EGFRI dermatologic toxicities: the European perspective.

Segaert S, Van Cutsem E. Segaert S, et al. Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):22-6. Oncology (Williston Park). 2007. PMID: 18159647 Free article.

4

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. McLellan B, et al. Among authors: segaert s. Ann Oncol. 2015 Oct;26(10):2017-26. doi: 10.1093/annonc/mdv244. Epub 2015 Jun 1. Ann Oncol. 2015. PMID: 26034039 Free PMC article. Review.

5

Skin toxicities of targeted therapies.

Segaert S, Chiritescu G, Lemmens L, Dumon K, Van Cutsem E, Tejpar S. Segaert S, et al. Eur J Cancer. 2009 Sep;45 Suppl 1:295-308. doi: 10.1016/S0959-8049(09)70044-9. Eur J Cancer. 2009. PMID: 19775626 No abstract available.

6

Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.

Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H. Hofheinz RD, et al. Among authors: segaert s. Crit Rev Oncol Hematol. 2017 Jun;114:102-113. doi: 10.1016/j.critrevonc.2017.03.032. Epub 2017 Apr 11. Crit Rev Oncol Hematol. 2017. PMID: 28477738 Free article. Review.

7

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.

Bernier J, Bonner J, Vermorken JB, Bensadoun RJ, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK. Bernier J, et al. Among authors: segaert s. Ann Oncol. 2008 Jan;19(1):142-9. doi: 10.1093/annonc/mdm400. Epub 2007 Sep 4. Ann Oncol. 2008. PMID: 17785763 Free article.

8

Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.

Segaert S, Hermans C. Segaert S, et al. Am J Clin Dermatol. 2017 Dec;18(6):771-787. doi: 10.1007/s40257-017-0296-7. Am J Clin Dermatol. 2017. PMID: 28597181 Review.

9

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.

Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P. Fidder H, et al. Among authors: segaert s. Gut. 2009 Apr;58(4):501-8. doi: 10.1136/gut.2008.163642. Epub 2008 Oct 2. Gut. 2009. PMID: 18832524

10

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.

Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, Epstein JB, Barasch A, Einhorn L, Wagner L, West DP, Rapoport BL, Kris MG, Basch E, Eaby B, Kurtin S, Olsen EA, Chen A, Dancey JE, Trotti A. Lacouture ME, et al. Among authors: segaert s. Support Care Cancer. 2010 Apr;18(4):509-22. doi: 10.1007/s00520-009-0744-x. Epub 2010 Feb 10. Support Care Cancer. 2010. PMID: 20145956

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page